Thomas Holbro

3.1k total citations · 1 hit paper
17 papers, 2.3k citations indexed

About

Thomas Holbro is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Thomas Holbro has authored 17 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Thomas Holbro's work include Complement system in diseases (5 papers), HER2/EGFR in Cancer Research (5 papers) and Pneumonia and Respiratory Infections (4 papers). Thomas Holbro is often cited by papers focused on Complement system in diseases (5 papers), HER2/EGFR in Cancer Research (5 papers) and Pneumonia and Respiratory Infections (4 papers). Thomas Holbro collaborates with scholars based in Switzerland, United States and United Kingdom. Thomas Holbro's co-authors include Nancy E. Hynes, Magdalena Koziczak, Roger R. Beerli, Francisca Maurer, Carlos F. Barbas, Gianluca Civenni, Richard M. Neve, Max M. Burger, Laura Lin and Gema Alonso and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Oncogene and Frontiers in Immunology.

In The Last Decade

Thomas Holbro

17 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

2003 777 citations Thomas Holbro, Roger R. Beerli et al. Proceedings of the National Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Holbro Switzerland	11	1.3k	1.3k	672	300	209	17	2.3k
Keng‐Hsueh Lan Taiwan	13	1.5k 1.2×	1.5k 1.2×	760 1.1×	381 1.3×	325 1.6×	21	2.5k
Joan T. Garrett United States	19	1.2k 0.9×	1.1k 0.9×	599 0.9×	392 1.3×	229 1.1×	30	2.0k
Edward Rosfjord United States	19	938 0.7×	1.0k 0.8×	358 0.5×	383 1.3×	271 1.3×	39	1.9k
Cammie Rinehart United States	15	1.7k 1.3×	1.7k 1.3×	719 1.1×	567 1.9×	327 1.6×	19	2.8k
Kendall D. Carey United States	10	951 0.7×	1.1k 0.8×	651 1.0×	373 1.2×	121 0.6×	12	1.9k
Ka Yin Kwong United States	14	1.7k 1.3×	1.2k 1.0×	339 0.5×	310 1.0×	353 1.7×	17	2.7k
Marc Webster Canada	14	1.2k 0.9×	1.3k 1.1×	424 0.6×	164 0.5×	292 1.4×	31	2.3k
José Jiménez Spain	14	893 0.7×	992 0.8×	407 0.6×	287 1.0×	268 1.3×	39	1.6k
Ben‐Quan Shen United States	19	797 0.6×	939 0.8×	749 1.1×	171 0.6×	164 0.8×	35	1.8k
Iwan Beuvink Switzerland	11	1.1k 0.9×	840 0.7×	272 0.4×	204 0.7×	304 1.5×	13	1.7k

Countries citing papers authored by Thomas Holbro

Since Specialization

Citations

This map shows the geographic impact of Thomas Holbro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Holbro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Holbro more than expected).

Fields of papers citing papers by Thomas Holbro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Holbro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Holbro. The network helps show where Thomas Holbro may publish in the future.

Co-authorship network of co-authors of Thomas Holbro

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Holbro. A scholar is included among the top collaborators of Thomas Holbro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Holbro. Thomas Holbro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Muri, Lukas, Marc Schmid, Anna Schubart, et al.. (2023). In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway. Frontiers in Immunology. 14. 5 indexed citations

Muri, Lukas, Anna Schubart, Christine Thorburn, et al.. (2022). Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b. Frontiers in Immunology. 13. 1020580–1020580. 7 indexed citations

Grand, Johannes, Ahmad Sajadieh, Lars Køber, et al.. (2022). Blood Pressure Drops During Hospitalization for Acute Heart Failure Treated With Serelaxin: A Patient-Level Analysis of 4 Randomized Controlled Trials. Circulation Heart Failure. 15(4). e009199–e009199. 1 indexed citations

Muri, Lukas, Anna Schubart, Christine Thorburn, et al.. (2021). Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals. Frontiers in Immunology. 12. 747594–747594. 21 indexed citations

Muri, Lukas, Anna Schubart, Christine Thorburn, et al.. (2021). Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals. Frontiers in Immunology. 12. 732146–732146. 19 indexed citations

Grand, Johannes, Ahmad Sajadieh, Lars Køber, et al.. (2021). Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure: An Analysis of Individual Patient Data From 4 Randomized Clinical Trials. Journal of the American Heart Association. 10(18). e022288–e022288. 8 indexed citations

Teerlink, John R., Marco Metra, Gad Cotter, et al.. (2020). Relationship Between Left Ventricular Ejection Fraction and Cardiovascular Outcomes Following Hospitalization for Heart Failure: Insights from the RELAX-AHF-2 Trial. European Journal of Heart Failure. 22(4). 726–738. 26 indexed citations

Webb, Nicholas J.A., Börje Haraldsson, Anna Schubart, et al.. (2020). MO042LNP023: A NOVEL ORAL COMPLEMENT ALTERNATIVE PATHWAY FACTOR B INHIBITOR FOR THE TREATMENT OF GLOMERULAR DISEASE. Nephrology Dialysis Transplantation. 35(Supplement_3). 5 indexed citations

Sato, Naoki, Carolyn S.P. Lam, John R. Teerlink, et al.. (2016). Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. Journal of Cardiac Failure. 23(1). 63–71. 21 indexed citations

10.

Holbro, Thomas & Nancy E. Hynes. (2004). ErbB Receptors: Directing Key Signaling Networks Throughout Life. The Annual Review of Pharmacology and Toxicology. 44(1). 195–217. 499 indexed citations

11.

Koziczak, Magdalena, Thomas Holbro, & Nancy E. Hynes. (2004). Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene. 23(20). 3501–3508. 133 indexed citations

12.

Civenni, Gianluca, Thomas Holbro, & Nancy E. Hynes. (2003). Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells ( EMBO reports , February 2003) (Correction). EMBO Reports. 4(3). 326–326. 1 indexed citations

13.

Civenni, Gianluca, Thomas Holbro, & Nancy E. Hynes. (2003). Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells. EMBO Reports. 4(2). 166–171. 103 indexed citations

14.

Holbro, Thomas. (2003). The ErbB receptors and their role in cancer progression. Experimental Cell Research. 284(1). 99–110. 492 indexed citations

15.

Holbro, Thomas, Roger R. Beerli, Francisca Maurer, et al.. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proceedings of the National Academy of Sciences. 100(15). 8933–8938. 777 indexed citations breakdown →

16.

Neve, Richard M., Thomas Holbro, & Nancy E. Hynes. (2002). Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells. Oncogene. 21(29). 4567–4576. 90 indexed citations

17.

Lin, Laura, et al.. (2001). Molecular interaction between human tumor marker protein p150, the largest subunit of eIF3, and intermediate filament protein K7. Journal of Cellular Biochemistry. 80(4). 483–490. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact